Literature DB >> 9683211

HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.

J Lisziewicz, H Jessen, D Finzi, R F Siliciano, F Lori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9683211     DOI： 10.1016/S0140-6736(98)24029-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

4.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

5.  In vitro hydroxyurea decreases Th1 cell-mediated immunity.

Authors:  A Weinberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

6.  Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.

Authors:  Giampiero Piccinini; Andrea Foli; Giuditta Comolli; Julianna Lisziewicz; Franco Lori
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Authors:  Deepti Saxena; Michael Spino; Fernando Tricta; John Connelly; Bernadette M Cracchiolo; Axel-Rainer Hanauske; Darlene D'Alliessi Gandolfi; Michael B Mathews; Jonathan Karn; Bart Holland; Myung Hee Park; Tsafi Pe'ery; Paul E Palumbo; Hartmut M Hanauske-Abel
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.